Botulinum Toxin Blocks Mast Cells and Prevents Rosacea Like Inflammation

Overview

Journal J Dermatol Sci

Publisher Elsevier

Specialty Dermatology

Date 2019 Jan 20

PMID 30658871

Citations 33

Authors

Jae Eun Choi

Tyler Werbel

Zhenping Wang

Chia Chi Wu

Tony L Yaksh

Anna Di Nardo

Affiliations

Soon will be listed here.

Abstract

Background: Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.

Objectives: To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.

Methods: Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.

Results: Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.

Conclusions: These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.

Citing Articles

Managing a Burning Face: Clinical Manifestations and Therapeutic Approaches for Neurogenic Rosacea.

Aedo G, Chahuan M, Gatica E, Herrera I, Parada L, Seguel A Int J Mol Sci. 2025; 26(5).

PMID: 40076987 PMC: 11901027. DOI: 10.3390/ijms26052366.

Casticin reduces rosacea-related inflammation by inhibiting mast cell activation via Mas-related G protein-coupled receptor X2.

Jia T, Xia Y, Yi M, Zhang X, Zheng Y, Che D Inflammopharmacology. 2025; .

PMID: 39821787 DOI: 10.1007/s10787-025-01639-8.

The Multifaceted Role of Botulinum Toxin A in Improving the Retention Rate of Fat Grafting.

Wang B, Chen Y, Dai Y Aesthetic Plast Surg. 2024; .

PMID: 39643703 DOI: 10.1007/s00266-024-04603-z.

Botulinum Toxin Effects on Freezing of Gait in Parkinson's Disease: A Systematic Review.

Tambasco N, Nigro P, Mechelli A, Duranti M, Parnetti L Toxins (Basel). 2024; 16(11).

PMID: 39591229 PMC: 11598804. DOI: 10.3390/toxins16110474.

Poly-d,l-Lactic Acid Via Transdermal Microjet Drug Delivery for Treating Rosacea in Asian Patients.

Seo S, Wan J, Thulesen J, Jalali A, Vitale M, Kim S J Cosmet Dermatol. 2024; 23(12):3993-3998.

PMID: 39248245 PMC: 11626325. DOI: 10.1111/jocd.16556.

References

Schiemann F, Brandt E, Gross R, Lindner B, Mittelstadt J, Sommerhoff C . The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4. J Immunol. 2009; 183(4):2223-31. DOI: 10.4049/jimmunol.0803587. View

Ramachandran R, Marino M, Paul S, Wang Z, Mascarenhas N, Pellett S . A Study and Review of Effects of Botulinum Toxins on Mast Cell Dependent and Independent Pruritus. Toxins (Basel). 2018; 10(4). PMC: 5923300. DOI: 10.3390/toxins10040134. View

Wilkins B, Chung L, Tublitz N, Wong B, Minson C . Mechanisms of vasoactive intestinal peptide-mediated vasodilation in human skin. J Appl Physiol (1985). 2004; 97(4):1291-8. DOI: 10.1152/japplphysiol.00366.2004. View

Two A, Wu W, Gallo R, Hata T . Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015; 72(5):749-58. DOI: 10.1016/j.jaad.2014.08.028. View

Holmes A, Steinhoff M . Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2016; 26(8):659-667. DOI: 10.1111/exd.13143. View

Suzuki K, Verma I . Phosphorylation of SNAP-23 by IkappaB kinase 2 regulates mast cell degranulation. Cell. 2008; 134(3):485-95. PMC: 2586340. DOI: 10.1016/j.cell.2008.05.050. View

Meng J, Wang J, Lawrence G, Dolly J . Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007; 120(Pt 16):2864-74. DOI: 10.1242/jcs.012211. View

Park T . The effects of botulinum toxin A on mast cell activity: preliminary results. Burns. 2012; 39(4):816-7. DOI: 10.1016/j.burns.2012.07.031. View

Dayan S, Ashourian N, Cho K . A Pilot, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of IncobotulinumtoxinA Injections in the Treatment of Rosacea. J Drugs Dermatol. 2017; 16(6):549-554. View

10.

Yamasaki K, Schauber J, Coda A, Lin H, Dorschner R, Schechter N . Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 2006; 20(12):2068-80. DOI: 10.1096/fj.06-6075com. View

11.

Yoshioka M, Fukuishi N, Kubo Y, Yamanobe H, Ohsaki K, Kawasoe Y . Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity. Biol Pharm Bull. 2008; 31(2):212-6. DOI: 10.1248/bpb.31.212. View

12.

Luu-The V, Paquet N, Calvo E, Cumps J . Improved real-time RT-PCR method for high-throughput measurements using second derivative calculation and double correction. Biotechniques. 2005; 38(2):287-93. DOI: 10.2144/05382RR05. View

13.

Kirshenbaum A, Metcalfe D . Growth of human mast cells from bone marrow and peripheral blood-derived CD34+ pluripotent progenitor cells. Methods Mol Biol. 2005; 315:105-12. DOI: 10.1385/1-59259-967-2:105. View

14.

Huynh T . Burden of Disease: The Psychosocial Impact of Rosacea on a Patient's Quality of Life. Am Health Drug Benefits. 2014; 6(6):348-54. PMC: 4031723. View

15.

Park H, Cho D, Kim H, Lee J, Cho B, Bang S . Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37. J Invest Dermatol. 2008; 129(4):843-50. PMC: 2665190. DOI: 10.1038/jid.2008.320. View

16.

Schiavo G, Matteoli M, Montecucco C . Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000; 80(2):717-66. DOI: 10.1152/physrev.2000.80.2.717. View

17.

Di Nardo A, Holmes A, Muto Y, Huang E, Preston N, Winkelman W . Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trial. J Am Acad Dermatol. 2016; 74(6):1086-92. DOI: 10.1016/j.jaad.2016.01.023. View

18.

Wollina U . The response of erythematous rosacea to ondansetron. Br J Dermatol. 1999; 140(3):561-2. DOI: 10.1046/j.1365-2133.1999.02744.x. View

19.

Dong M, Yeh F, Tepp W, Dean C, Johnson E, Janz R . SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006; 312(5773):592-6. DOI: 10.1126/science.1123654. View

20.

Peng C, Zhu G, Liu X, Li H . Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C. Neurosci Bull. 2018; 34(5):747-758. PMC: 6129247. DOI: 10.1007/s12264-018-0230-x. View